Amgen Issues Credit to 340B Covered Entities Due to Miscalculation of Drug Ceiling Price
Posted on
AAFCPAs would like to make clients aware of potential credits owed to your organization as a result of a miscalculation of a drug ceiling price. Recently, the drug manufacturer Amgen USA Inc. notified the Health Resources and Services Administration (HRSA) that the 340B ceiling price for multiple products had been calculated incorrectly and that credits may be owed to affected covered entities.
Amgen stated that the ceiling price was improperly calculated from October 2006 through March 2015 on products using NDC labeler codes 55513 and 58406. This includes: Aranesp®, Enbrel®, Epogen®, Neulasta®, Neupogen®, Vectibix®, Nplate®, Prolia®, and Sensipar®. Affected covered entities should receive a credit within the next three to four months based upon activity with the manufacturer, accompanied by a letter detailing the change in price.
AAFCPAs encourages healthcare clients participating in the 340B drug pricing program to click here to review the full listing of affected National Drug Codes (NDCs). >> If you feel that you were overcharged for the purchase of a 340B covered outpatient drug, you may contact Amgen directly at 340BRelations@nullamgen.com.
AAFCPAs delivers a full range of solutions solving the challenges that AAF’s healthcare clients face, including: guidance on compliance with 340B pharmacy program requirements, and program audits of both on-site and contract pharmacies. If you have any questions or need additional information, please contact your AAF Partner, or Courtney McFarland, CPA: 774.512.4051, cmcfarland@nullaafcpa.com.
Courtney is an audit & consulting partner in the firm’s Healthcare Practice with extensive experience advising the nation's healthcare safety net community, including Federally Qualified Heath Centers (FQHCs), clinics, and behavioral health providers. She delivers a full range of solutions solving the challenges that AAFCPAs’ healthcare clients face, including: audits in accordance with Uniform Guidance/Single Audit and Government Auditing Standards, 340B pharmacy program requirements, best practices for reconciliation & analysis of statistical and programmatic data, …
0
We use cookies to ensure we give you the best experience on our website. By continuing your visit, you consent to the use of these cookies. See our:
Functional cookies
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
